Physician profile
Binusha Moitheennazima
NPI 1760658330
$15,489.01
in general payments reported to CMS, 2019-2025
37 companies · $7,434 in 2025
The $7,434 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $808 · 2021: $1,048 · 2022: $1,098 · 2023: $1,912 · 2024: $1,830 · 2025: $7,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,976 · Consulting Fee: $5,076 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,976.41 |
| Consulting Fee | $5,076.00 |
| Education | $123.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,796.58 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $2,170.31 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.17 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Mylan Specialty L.P. | $565.66 | 2019-2024 | Yupelri, Yupelri |
| Genzyme Corporation | $558.28 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $356.78 | 2019-2025 | |
| Verona Pharma, INC. | $310.51 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $266.99 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $242.01 | 2019-2025 | Dupixent |
| Amgen INC. | $225.91 | 2022-2025 | Tezspire |
| Philips North America LLC | $215.55 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Paratek Pharmaceuticals, INC. | $214.34 | 2021-2023 | Nuzyra |
| Actelion Pharmaceuticals US, INC. | $151.96 | 2019-2022 | |
| Genentech USA, INC. | $140.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.84 | 2021-2023 | Glassia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.20 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $101.13 | 2021-2025 | Winrevair |
| Harmony Biosciences LLC | $99.26 | 2020-2022 | |
| Viatris Specialty LLC | $97.72 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $91.99 | 2025 | Inspire |
| Insmed, INC. | $87.71 | 2022-2025 | Arikayce |
| Ani Pharmaceuticals, INC. | $72.78 | 2023-2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $68.37 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Sanofi-Aventis U.S. LLC | $68.08 | 2019-2020 | |
| Pulmonx Corporation | $60.79 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Ars Pharmaceuticals Operations, INC. | $53.51 | 2025 | Neffy |
| Advanced Respiratory, INC | $50.65 | 2019-2021 | |
| Electromed, INC. | $43.23 | 2022 | |
| Lilly USA, LLC | $41.33 | 2025 | Zepbound |
| Vapotherm INC | $29.50 | 2022 | |
| Vifor Pharma, INC. | $28.41 | 2024 | Veltassa |
| Janssen Pharmaceuticals, INC | $26.73 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.68 | 2021 | |
| Kaleo, INC. | $18.64 | 2020 | |
| Resmed Corp | $16.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2022 | |
| United Therapeutics Corporation | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binusha Moitheennazima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.